We are live on ! Find out more
TRDA icon

Entrada Therapeutics
TRDA

114 hedge funds and large institutions have $269M invested in Entrada Therapeutics in 2025 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 35 increasing their positions, 42 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

103% more call options, than puts

Call options by funds: $229K | Put options by funds: $113K

50% more capital invested

Capital invested by funds: $179M → $269M (+$90.1M)

7% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 15

3% less funds holding

Funds holding: 117 → 114 (-3)

10.97% less ownership

Funds ownership: 79.44% → 68.47% (-11%)

17% less repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 42

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

Holders
114
Holders Change
-3
Holders Change %
-2.56%
% of All Funds
1.39%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.04%
New
16
Increased
35
Reduced
42
Closed
15
Calls
$229K
Puts
$113K
Net Calls
+$116K
Net Calls Change
+$86K

Top Buyers

1
TCM
TCG Crossover Management
California
+$12.7M
2
BBA
Baker Bros. Advisors
New York
+$1.74M
3
WP
Woodline Partners
California
+$1.2M
4
SFM
Sphera Funds Management
Israel
+$935K
5
BlackRock
BlackRock
New York
+$870K

Top Sellers

1
Renaissance Technologies
Renaissance Technologies
New York
-$2.88M
2
Millennium Management
Millennium Management
New York
-$2.86M
3
5VM
5AM Venture Management
California
-$1.69M
4
Jane Street
Jane Street
New York
-$1.36M
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$1.02M
Name Holding Trade Value Shares
Change 		Change in
Stake
BBA
1
Baker Bros. Advisors
New York
$52.1M +$1.74M +206,911 +4%
5VM
2
5AM Venture Management
California
$41.7M -$1.69M -200,000 -5%
BlackRock
3
BlackRock
New York
$22.1M +$870K +103,216 +5%
TCM
4
TCG Crossover Management
California
$21.5M +$12.7M +1,503,437 +257%
MC
5
Merck & Co
New Jersey
$17.9M – – –
Vanguard Group
6
Vanguard Group
Pennsylvania
$16.8M +$238K +28,235 +2%
Wellington Management Group
7
Wellington Management Group
Massachusetts
$10.7M +$761K +90,339 +9%
SG
8
StepStone Group
California
$7.83M – – –
Geode Capital Management
9
Geode Capital Management
Massachusetts
$6.58M -$43.6K -5,172 -0.8%
State Street
10
State Street
Massachusetts
$5.23M +$85.8K +10,174 +2%
Millennium Management
11
Millennium Management
New York
$5.12M -$2.86M -338,914 -41%
Jacobs Levy Equity Management
12
Jacobs Levy Equity Management
New Jersey
$3.73M +$396K +46,976 +15%
T. Rowe Price Associates
13
T. Rowe Price Associates
Maryland
$3.37M -$279K -33,103 -9%
Acadian Asset Management
14
Acadian Asset Management
Massachusetts
$3.19M +$109K +12,890 +4%
Citadel Advisors
15
Citadel Advisors
Florida
$3.01M -$362K -42,971 -13%
Dimensional Fund Advisors
16
Dimensional Fund Advisors
Texas
$2.81M -$1.02M -120,901 -31%
Morgan Stanley
17
Morgan Stanley
New York
$2.68M -$729K -86,505 -25%
Renaissance Technologies
18
Renaissance Technologies
New York
$2.6M -$2.88M -341,665 -57%
RA
19
Royce & Associates
New York
$2.54M -$829K -98,360 -28%
Northern Trust
20
Northern Trust
Illinois
$2.33M -$230K -27,306 -11%
Charles Schwab
21
Charles Schwab
California
$2.27M +$304K +36,010 +19%
Goldman Sachs
22
Goldman Sachs
New York
$2.11M -$145K -17,163 -8%
BNP Paribas Financial Markets
23
BNP Paribas Financial Markets
France
$1.86M +$276K +32,757 +22%
Qube Research & Technologies (QRT)
24
Qube Research & Technologies (QRT)
United Kingdom
$1.81M -$943K -111,855 -39%
WP
25
Woodline Partners
California
$1.46M +$1.2M +142,110 New
1
2 3 4 5

TRDA Hedge Fund Activity: Q4 2025 in Review

114 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Entrada Therapeutics (TRDA) for Q4 2025, worth a combined $269M — up 50% from $179M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new TRDA positions and 15 closed out — a net gain of 1 holder — while 35 added to existing stakes and 42 trimmed.

The largest buyer was TCG Crossover Management, adding an estimated $12.7M. The largest seller was Renaissance Technologies, cutting an estimated $2.88M.

  • 114 institutional investors held Entrada Therapeutics (TRDA) as of Q4 2025, down from 117 in Q3 2025.
  • Funds reported $269M of Entrada Therapeutics stock for Q4 2025, up 50% quarter-over-quarter.
  • 16 funds opened new Entrada Therapeutics positions in Q4 2025 and 15 closed out, a net change of +1 holder.
  • The largest Entrada Therapeutics buyer in Q4 2025 was TCG Crossover Management, an estimated $12.7M added.
  • The largest Entrada Therapeutics seller in Q4 2025 was Renaissance Technologies, an estimated $2.88M sold.

Based on aggregated 13F filings for Q4 2025.